vivaCT80 - in vivo small animal microCT

vivaCT80 - 小动物体内显微 CT

• 批准号: 8639867
• 负责人: Daniel S Perrien
• 金额: $ 41.4万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-06-01 至 2015-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8639867
• 关键词: Acute; Affect; Alzheimer' s Disease; Animals; Collaborations; Communicable Diseases; Ensure; Fostering; Funding; Grant; Housing; Image; Institutes; Institution; Life; Low Dose Radiation; Magnetic Resonance Imaging; Malignant neoplasm of prostate; Manufacturer Name; Multiple Myeloma; Mus; Optics; Pilot Projects; Positron-Emission Tomography; Primates; Research Project Grants; Resolution; Scanning; Science; Soft Tissue Neoplasms; Specimen; System; Time; United States National Institutes of Health; Universities; X-Ray Computed Tomography; angiogenesis; attenuation; bone quality; drug development; imaging modality; improved; in vivo; instrument; malignant breast neoplasm; repaired; skeletal; substantia spongiosa; success

DESCRIPTION (provided by applicant): This application is to replace an existing microCAT that already supports multiple NIH-funded projects but is failing and cannot be repaired. The replacement system will support all of the current projects and have higher resolution, faster scan time, and lower radiation dose that will enable new applications, expanding usage to additional research projects. In vivo micro computed tomography systems are used for non-destructive three dimensional analyses of synthetic, ex vivo specimens, and, most importantly, live animals. Two of the four quadrants on our existing microCAT II have failed and cannot be repaired because the manufacturer of that instrument no longer supports parts replacement. The proposed vivaCT80 system is the first and only in vivo microCT system currently available that can produce images at a resolution sufficient for analysis of murine trabecular bone and microvasculature, low radiation dose, and possesses a bore size large enough to accommodate animals as large as small primates. Many current users depend on in vivo microCT for coregistration and attenuation calculations with PET, MRI, and optical CT (FMT, Visen). Hence, the loss of in vivo microCT imaging capabilities will affect multiple imaging platforms and projects across a wide range of biomedical fields. Thus, the vivCT80 will provide years of stable support for existing users and expand numerous, wide ranging, NIH funded projects as well as pilot projects for new users and projects. Supported projects study angiogenesis, skeletal consequences of breast and prostate cancer and multiple myeloma, bone quality, endochondral ossification, Alzheimer's disease, drug development, acute infectious disease, and a range of soft tissue tumors, among others. Aspects of each of these projects either require or will be substantially enhanced by reliable, fast, in vivo microCT imaging. Due to its improved capabilities, the vivaCT80 will undoubtedly foster collaborations within Vanderbilt University and at neighboring institutions. Housing this instrument in the Vanderbilt University Institute for Imaging Science (VUIIS), which has been highly successful in managing numerous imaging modalities, will ensure campus wide access and superior management. Acquisition of a new in vivo microCT is absolutely critical to the continued success of many NIH- funded grants at Vanderbilt.

描述（由申请人提供）：此申请是替换已经支持多个NIH资助项目但无法修复的现有的微型电脑。替代系统将支持当前所有项目，并具有更高的分辨率，更快的扫描时间和较低的辐射剂量，从而可以实现新的应用程序，从而扩展了对其他研究项目的用法。体内微型计算机断层扫描系统用于合成，离体样本的非破坏性三维分析，最重要的是活动物。我们现有的Microcat II上的四个象限中的两个已经失败，无法修复，因为该仪器的制造商不再支持零件更换。拟议的Vivact80系统是目前可用的第一个也是唯一的体内微型系统系统，可以以足以分析小鼠小梁骨和微血管造成的分辨率产生图像，低辐射剂量，并且具有足够大的孔大小，足以容纳与小型灵长类动物一样大的动物。许多当前的用户依靠体内微观可用于使用PET，MRI和光学CT（FMT，Visen）进行核心施用和衰减计算。因此，体内Microct成像功能的丧失将影响各种生物医学领域的多个成像平台和项目。因此，VIVCT80将为现有用户提供多年的稳定支持，并扩展众多，NIH资助的项目以及针对新用户和项目的试点项目。支持的项目研究血管生成，乳腺癌和前列腺癌的骨骼后果以及多发性骨髓瘤，骨骼质量，内侧软骨骨化，阿尔茨海默氏病，药物发育，急性传染病以及一系列软组织肿瘤等。这些项目中每个项目的各个方面都需要或通过可靠，快速，在体内Microct成像来大大增强。由于其功能的提高，Vivact80无疑将促进范德比尔特大学和邻近机构的合作。在范德比尔特大学成像科学研究所（VUIIS）中设有该工具，该工具在管理众多成像方式方面非常成功，将确保校园广泛的访问和优越的管理。获取新的体内微观批准对于范德比尔特（Vanderbilt）许多由NIH资助的赠款的持续成功至关重要。